期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 39, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-020-01749-x
关键词
-
类别
资金
- Targeted Therapy Fund of Chinese Society of Clinical Oncology [Y-sy2018-075, Y-HR2015-139]
- Outstanding Youth Project of Shaanxi Province [2020JC-35]
- Wu Jieping Medical Foundation [320.6750.19094-51]
The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle to the prospect of ICI treatment. IrAEs are a discrete toxicity caused by the nonspecific activation of the immune system and can affect almost all tissues and organs. Currently, research on biomarkers mainly focuses on the gastrointestinal tract, endocrine system, skin and lung. Several potential hypotheses concentrate on the overactivation of the immune system, excessive release of inflammatory cytokines, elevated levels of pre-existing autoantibodies, and presence of common antigens between tumors and normal tissues. This review lists the current biomarkers that might predict irAEs and their possible mechanisms for both nonspecific and organ-specific biomarkers. However, the prediction of irAEs remains a major clinical challenge to screen and identify patients who are susceptible to irAEs and likely to benefit from ICIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据